OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Meta Expands AI Training With Employee Activity Tracking Tools 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
CHICAGO, May 24, 2017 -- Allscripts shareholders elected Mara G. Aspinall to serve as director. Aspinall is president and CEO of Health Catalysts, an investment and advisory firm dedicated to the growth of new healthcare companies. Aspinall is also executive chairman of GenePeeks, a computational genomics company, and is a member of the Board of Directors of Abcam plc (AIM:ABC), Castle Biosciences and Blue Cross Blue Shield Arizona. All of Allscripts other current directors were also reelected.
“Mara has deep industry knowledge and we’re honored to welcome her to the Board of Directors,” said Allscripts CEO Paul M. Black. “Her passion for innovation and keen insights will strengthen our ability to lead the change in health care.”
Prior to joining Health Catalysts, Aspinall was president and CEO of Ventana Medical Systems division of Roche, a worldwide leader in development and commercialization of tissue-based cancer diagnostics. She previously spent 12 years as president of Genzyme Genetics and Genzyme Pharmaceuticals.
In addition to running commercial enterprises, Aspinall co-founded the International School of Biomedical Diagnostics at Arizona State University, the first school dedicated entirely to Diagnostics as an independent discipline.
Mara started her business career at the strategic consulting firm Bain & Company. She holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.
About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
© 2017 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.
For more information contact: Investors: Seth Frank 312-506-1213 [email protected] Media: Tom Lynch 312-386-6765 [email protected]
